COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year profit and sales forecasts on Wednesday as sales growth ...

Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes ...

Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to ...

The deal is with drugmakers Eli Lilly and Novo Nordisk to cut prices of their weight-loss drugs and expand Medicare coverage ...

A new US government deal with drugmakers Eli Lilly and Novo Nordisk will slash prices for popular weight-loss drugs like ...

Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for their weight management indications for people with ...

Seniors could soon pay just $50 a month for Ozempic and other drugs used for weight loss under a new Trump plan to cut prescription costs.

The Danish pharmaceutical giant Novo Nordisk has struck an agreement with the Centers for Medicare & Medicaid Services (CMS) ...

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...

President Trump announces expanded coverage and reduced prices for obesity treatments Zepbound and Wegovy, addressing patient ...

President Donald Trump announced that his administration has finally struck a deal with Novo Nordisk and Eli Lilly to reduce ...

Popular GLP-1 drugs like Ozempic will get cheaper in exchange for partial Medicare coverage, opening up new markets for Eli ...